Activation of endothelial and coagulation systems in left ventricular assist device recipients

Ranjit John1, Sandhya Panch, Jennifer Hrabe

  • 1Division of Cardiothoracic Surgery, Department of Surgery, University of Minnesota, Minneapolis, Minnesota 55455, USA. johnx008@umn.edu

Insights

Left ventricular assist device recipients show early and prolonged activation of endothelial and coagulation systems. These changes, particularly involving tissue factor, suggest a sustained risk of thrombosis due to endothelial dysfunction.

Area of Science:

  • Cardiovascular Research
  • Hematology
  • Biomedical Engineering

Background:

  • Paucity of organ donors drives research into alternatives like left ventricular assist devices (LVADs).
  • LVADs are used as bridge-to-transplant and destination therapy, but complications like hemorrhage and thrombosis limit their use.
  • Understanding changes in endothelial and coagulation systems in LVAD recipients is crucial.

Purpose of the Study:

  • To investigate temporal changes in endothelial dysfunction and coagulation markers in LVAD recipients.
  • To compare these changes with control patients undergoing non-LVAD cardiac surgery.

Main Methods:

  • Studied markers of endothelial dysfunction (circulating endothelial cells, E-selectin, VCAM, ICAM, tissue factor).
  • Assessed thrombin generation (prothrombin fragments 1,2, thrombin/antithrombin) and fibrinolysis (D-dimer).
  • Monitored 21 LVAD recipients and 7 control patients at multiple postoperative time points.

Main Results:

  • LVAD recipients had significantly higher baseline levels of ICAM, E-selectin, tissue factor, thrombin/antithrombin, and D-dimer compared to normal ranges.
  • Thrombin generation and fibrinolysis markers peaked postoperatively and normalized by 3 months.
  • Endothelial markers (ICAM, E-selectin, tissue factor) remained elevated for up to 6 months in LVAD recipients, unlike controls.

Conclusions:

  • LVAD recipients exhibit significant baseline activation of endothelial and coagulation systems, intensified postoperatively.
  • Prolonged activation suggests the extrinsic pathway of thrombosis, mediated by sustained endothelial dysfunction.
  • Further research is needed to clarify the clinical impact of these observed changes.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.